基本情報
- CAS
139145-84-9- 標準SMILES
Cl.O=c1[nH]nc(OCCCc2ccc(Cl)cc2)c(NCc2cccnc2)c1Br- InChIKey
QWGUGDYWUADMGB-UHFFFAOYSA-N- 分子式
- C19H19BrCl2N4O2
- 平均分子量
- 486.2 g/mol
- 単同位体質量
- 484.00684
概要
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans. M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis, and asthma. In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. Intermittent claudication is a major symptom of arteriosclerosis obliterans. It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. It is estimated that about 6 million people suffer from intermittent claudication in the USA, with only 10 percent of these people currently receiving treatment. Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited
名称と識別子
- 優先名称
- NM-702
- IUPAC
- 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochloride
名称と別名
NM-702RefChem:858687Parogrelil hydrochloride878796-94-265O9DMS368UNII-65O9DMS368139145-84-93(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1)5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1H-pyridazin-6-one;hydrochlorideNM702Parogrelil (hydrochloride)orb1699721
名称をさらに表示
SCHEMBL1739368QWGUGDYWUADMGB-UHFFFAOYSA-NDTXSID701007830AKOS0407491174-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochlorideCS-0034672T282964-Bromo-6-[3-(4-chlorophenyl)propoxy]-5-{[(pyridin-3-yl)methyl]amino}pyridazin-3-ol--hydrogen chloride (1/1)
データベース識別子
- CAS
139145-84-9、878796-94-2- PubChem CID
- 9848253
- DTXSID
DTXSID701007830- UNII
- 65O9DMS368
物性
構造計算による物性
- 極性表面積
- 75.6 Ų
- 水素結合供与体数
- 3
- 水素結合受容体数
- 5
- 回転可能結合数
- 8
- 重原子数
- 28
- 形式電荷
- 0
- 複雑度
- 576
化学と産業
薬理情報
Pharmacodynamics
Intermittent claudication is a major symptom of arteriosclerosis obliterans. It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries. Patients with claudication experience significant disability, owing to their exercise limitation. Therapeutic options to improve exercise performance in these patients are limited. NM-702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase.
Mechanism of ActionNM-702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase.
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…